不同抗肿瘤治疗方式对PD-L1表达的影响及相关机制  

The effect of different anti-tumor treatments on the expression of PD-L1 and related mechanisms

作　　者：叶丽静 虞亦鸣[1] YE Lijing;YU Yiming(Department of Respiratory and Critical Care,Affiliated Hospital of Ningbo University School of Medicine,Ningbo 315020,China)

机构地区：[1]宁波大学医学院附属医院呼吸及危重症学科,宁波315020

出　　处：《生命的化学》2022年第1期56-62,共7页Chemistry of Life

基　　金：浙江省自然科学基金项目(2018A610271)。

摘　　要：程序性死亡受体-1/配体-L1(PD-1/PD-L1)抑制剂作为免疫治疗的新型药物,常与放化疗、靶向治疗等联合应用到各种恶性肿瘤的治疗中,目前认为PD-L1表达率可预测PD-L1抑制剂疗效。而不同的抗肿瘤治疗会对PD-L1的表达产生不同的影响,因此明确不同抗肿瘤治疗方式对PD-L1表达水平的影响以及相关机制显得十分重要。本文总结了不同抗肿瘤治疗方式对PD-L1表达的影响以及其发生机制,指出了肿瘤患者在接受免疫治疗前以及治疗期间,需行二次甚至多次活检来明确肿瘤组织的PD-L1表达情况,以协助临床医师判断是否可以施行联合免疫治疗,帮助患者有更好的生存获益。In recent years,programmed death receptor-1/ligand-L1(PD-L1)inhibitors are often used in combination with radiotherapy,chemotherapy,and targeted therapy in the treatment of various malignant tumors.It is currently believed that the expression rate of PD-L1 can predict PD-L1 efficacy of L1 inhibitor.This paper reviewed many domestic and foreign studies on the effects and mechanisms of different anti-tumor treatments on PD-L1 expression and found that there are differences in the effects of different treatment options on PD-L1 expression and the mechanisms involved.It is pointed out that before and during treatment,tumor patients need to undergo two or even multiple biopsies to confirm the expression of PD-L1 in tumor tissues,so as to assist clinicians in determining whether to combine immunotherapy,so that patients can have better survival benefits.

关 键 词：PD-1/PD-L1 放化疗 靶向治疗 免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]